Skip to main content

Table 3 Subgroup analysis by study population

From: Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials

Subgroups

Number of studies (number of patients)

Risk ratio of AKI (95% CI)

P -value (test for effect)

Heterogeneity

ARDS

4 (919)

1.55 (1.15 to 2.09)

0.005

I 2 = 0%

Non-ARDS

6 (418)

0.90 (0.49 to 1.67)

0.75

I 2 = 0%

Surgery

4 (289)

0.89 (0.45 to 1.75)

0.73

I 2 = 0%

Sepsis

1 (49)

1.77 (0.17 to 18.26)

0.63

Not applicable

Pediatric hypoxemic respiratory failure

1 (80)

0.67 (0.10 to 4.49)

0.68

Not applicable

  1. AKI, acute kidney injury; ARDS, acute respiratory distress syndrome.